Tweet
I started working on whole genome sequencing and exome sequencing with Illumina HiSeq 2000 and also with 454 sequencer. Can anybody please help me to understand the data analysis of the sequenced reads????
-
-
If you'd like answers to such a question, you should start by posting in the correct forum. Then, explain what you want to do with the reads. You're query can be condensed to "I ran an experiment; how do I analyze it?", and nobody can really help you without some real detail.Originally posted by rd69 View Post -
Anyone remember the days were you just dumped 3 volumes of Maniatis on a student desk and turned around... probably not.Originally posted by rd69 View PostComment
-
Moved this to a new thread...and I really encourage the original poster to read the following:
Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment